Cardiorenal Syndrome Type 4: Management

被引:17
作者
Clementi, Anna [1 ,2 ]
Virzi, Grazia Maria [2 ,3 ]
Brocca, Alessandra [2 ,3 ]
de Cal, Massimo [2 ,3 ]
Vescovo, Giorgio [4 ]
Granata, Antonio [1 ]
Ronco, Claudio [2 ,3 ]
机构
[1] Dept Nephrol & Dialysis, Agrigento, Italy
[2] San Bortolo Hosp, IRRIV, IT-36100 Vicenza, Italy
[3] San Bortolo Hosp, Dept Nephrol Dialysis & Transplantat, IT-36100 Vicenza, Italy
[4] San Bortolo Hosp, Dept Internal Med, IT-36100 Vicenza, Italy
关键词
Cardiorenal syndrome; Cardiovascular risk factors; Chronic kidney disease; Dialysis; Kidney function; Renocardiac syndrome; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR EVENTS EVOLVE; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; FLUX HEMODIALYSIS; DIALYSIS PATIENTS; RANDOMIZED-TRIAL; CARDIAC-DISEASE; ASSOCIATION; MORTALITY;
D O I
10.1159/000356369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiorenal syndrome (CRS) type 4, or chronic renocardiac syndrome, has been defined as 'chronic abnormalities in renal function leading to cardiac disease' and recognizes the extreme burden of cardiovascular (CV) disease (CVD) risk in patients with chronic kidney disease (CKD). CKD is common and increasingly recognized as a risk factor for CVD. Although during the past 10 years CV morbidity and mortality have decreased markedly in the general population, their rates still remain high among CKD patients. For this reason, CKD patients should be evaluated thoroughly for CV risk factors which require an aggressive management, given the significant implications of CRS type 4 at both individual and societal level. We will review the management of the most important conventional and nonconventional CVD risk factors related to CKD. (C) 2013 S. Karger AG, Basel
引用
收藏
页码:200 / 209
页数:10
相关论文
共 72 条
[1]   β-Blocker use in long-term dialysis patients -: Association with hospitalized heart failure and mortality [J].
Abbott, KC ;
Trespalacios, FC ;
Agodoa, LY ;
Taylor, A ;
Bakris, GL .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (22) :2465-2471
[2]   On-line predilution hemofiltration versus ultrapure high-flux hemodialysis: A multicenter prospective study in 23 patients [J].
Altieri, P ;
Sorba, GB ;
Bolasco, PG ;
Bostrom, M ;
Asproni, E ;
Ferrara, R ;
Bolasco, F ;
Cossu, M ;
Cadinu, F ;
Cabiddu, GF ;
Casu, D ;
Ganadu, M ;
Passaghe, M ;
Pinna, M .
BLOOD PURIFICATION, 1997, 15 (03) :169-181
[3]  
AMORE A, 1995, J AM SOC NEPHROL, V6, P1278
[4]   Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation [J].
Andress, DL .
KIDNEY INTERNATIONAL, 2006, 69 (01) :33-43
[5]  
[Anonymous], HYPERTENSION S
[6]  
[Anonymous], J NEPHROL
[7]  
[Anonymous], LANDSCOPE
[8]  
[Anonymous], COCHRANE DATABASE SY
[9]   Bacteremia Associated with Tunneled Hemodialysis Catheters: Outcome after Attempted Salvage [J].
Ashby, Damien R. ;
Power, Albert ;
Singh, Seema ;
Choi, Peter ;
Taube, David H. ;
Duncan, Neill D. ;
Cairns, Tom D. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (10) :1601-1605
[10]   Efficacy and safety of haemodialysis treatment with the Hemocontrol™ biofeedback system:: a prospective medium-term study [J].
Basile, C ;
Giordano, R ;
Vernaglione, L ;
Montanaro, A ;
De Maio, P ;
De Padova, F ;
Marangi, AL ;
Di Marco, L ;
Santese, D ;
Semeraro, A ;
Ligorio, VA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (02) :328-334